Review





Similar Products

96
Santa Cruz Biotechnology cyclin dependent kinase inhibitor 2a p16ink4a p16
LT-NPs-NIR protects TSPCs against oxidative stress-induced senescence and preserves tenogenic phenotype. (A–D) Immunofluorescence staining for DNA damage (γ-H2AX), proliferation (Ki67), and senescence markers <t>(P16,</t> P53). (E–G) Assessment of stemness (SOX2) and tenogenic differentiation markers (SCX, COL1). (H) Quantitative analysis of the indicated markers. (I) qRT-PCR analysis of SASP-related inflammatory mediators (IL-1β, CXCL10) and matrix-degrading enzymes (MMP3, MMP13). (J) Schematic illustrating the mechanism of ROS scavenging and SASP inhibition. Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Snt: senescent cells; Yng: young cells.
Cyclin Dependent Kinase Inhibitor 2a P16ink4a P16, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/p16+Antibody/pmc12813888-123-49-56
Average 96 stars, based on 1 article reviews
cyclin dependent kinase inhibitor 2a p16ink4a p16 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
MedChemExpress cyclin dependent kinase cdk inhibitors
Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with <t>CDK</t> and NOTCH <t>inhibitors</t> starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.
Cyclin Dependent Kinase Cdk Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/Palbociclib/pmc13116222-42-24-31
Average 96 stars, based on 1 article reviews
cyclin dependent kinase cdk inhibitors - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology cyclin dependent kinase inhibitor 1a
Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with <t>CDK</t> and NOTCH <t>inhibitors</t> starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.
Cyclin Dependent Kinase Inhibitor 1a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/p21+Antibody/pm41839900-137-51-56
Average 96 stars, based on 1 article reviews
cyclin dependent kinase inhibitor 1a - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

86
G1 Therapeutics heteroaryl pyrrolo 3 2 d pyrimidin 2 amine cyclin dependent kinase inhibitors
Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with <t>CDK</t> and NOTCH <t>inhibitors</t> starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.
Heteroaryl Pyrrolo 3 2 D Pyrimidin 2 Amine Cyclin Dependent Kinase Inhibitors, supplied by G1 Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/2+2+3+amine+cyclin+d+dependent+heteroaryl+inhibitors+kinase+n+pyrimidin+pyrrolo/us12565502-938-25-19
Average 86 stars, based on 1 article reviews
heteroaryl pyrrolo 3 2 d pyrimidin 2 amine cyclin dependent kinase inhibitors - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

96
Proteintech rabbit anti cyclin dependent kinase inhibitor 1a
Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with <t>CDK</t> and NOTCH <t>inhibitors</t> starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.
Rabbit Anti Cyclin Dependent Kinase Inhibitor 1a, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/P21+Antibody/pm41750561-49-17-36
Average 96 stars, based on 1 article reviews
rabbit anti cyclin dependent kinase inhibitor 1a - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
Cusabio el005089hu
Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with <t>CDK</t> and NOTCH <t>inhibitors</t> starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.
El005089hu, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cycline-dependent+kinase+inhibitor/Human+Cyclin-dependent+kinase+inhibitor+%2C+isoforms+1%2F2%2F3(CDKN2A)+ELISA+kit/pmc12765743-37-30-32
Average 94 stars, based on 1 article reviews
el005089hu - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


LT-NPs-NIR protects TSPCs against oxidative stress-induced senescence and preserves tenogenic phenotype. (A–D) Immunofluorescence staining for DNA damage (γ-H2AX), proliferation (Ki67), and senescence markers (P16, P53). (E–G) Assessment of stemness (SOX2) and tenogenic differentiation markers (SCX, COL1). (H) Quantitative analysis of the indicated markers. (I) qRT-PCR analysis of SASP-related inflammatory mediators (IL-1β, CXCL10) and matrix-degrading enzymes (MMP3, MMP13). (J) Schematic illustrating the mechanism of ROS scavenging and SASP inhibition. Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Snt: senescent cells; Yng: young cells.

Journal: Bioactive Materials

Article Title: On-demand mild photothermal cascade platform reprogramming mitochondrial immunity for tendon rejuvenation

doi: 10.1016/j.bioactmat.2026.01.004

Figure Lengend Snippet: LT-NPs-NIR protects TSPCs against oxidative stress-induced senescence and preserves tenogenic phenotype. (A–D) Immunofluorescence staining for DNA damage (γ-H2AX), proliferation (Ki67), and senescence markers (P16, P53). (E–G) Assessment of stemness (SOX2) and tenogenic differentiation markers (SCX, COL1). (H) Quantitative analysis of the indicated markers. (I) qRT-PCR analysis of SASP-related inflammatory mediators (IL-1β, CXCL10) and matrix-degrading enzymes (MMP3, MMP13). (J) Schematic illustrating the mechanism of ROS scavenging and SASP inhibition. Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Snt: senescent cells; Yng: young cells.

Article Snippet: After washing, cells were incubated with primary antibodies against Ki67 (ab15580, Abcam), Phosphorylated Histone H2AX (γ-H2AX) (ab81299, Abcam), SOX2 (sc-365964, Santa Cruz), Type I Collagen (COL1) (ab138492, Abcam), tenomodulin (TNMD) (ab203676, Abcam; sc-51813, Santa Cruz), Scleraxis (SCX) (sc-518082, Santa Cruz), IRF3 (ab68481, Abcam), Transcription Factor p65/RELA (P65) (A22331, Abclonal), Cyclin-Dependent Kinase Inhibitor 2A (p16INK4a) (P16) (sc-1661, Santa Cruz), P53 (10442-1-AP, Proteintech), Inducible Nitric Oxide Synthase (iNOS) (ab178945, Abcam), Arginase-1(Arg-1) (ab96183, Abcam), HSP70 (sc-32239, Santa Cruz), IL-6 (ab233706, Abcam), Matrix Metalloproteinase 13 (MMP13) (ab39012, Abcam), Double-stranded DNA (dsDNA) Marker (sc-58749, Santa Cruz), and Translocase of Outer Mitochondrial Membrane 20 (TOMM20) (11802-1-AP, Proteintech).

Techniques: Immunofluorescence, Staining, Quantitative RT-PCR, Inhibition

LT-NPs-NIR modulate macrophage polarization and enhance TSPC-mediated tenogenic repair in a Transwell co-culture system. (A) Schematic of the Transwell co-culture setup. (B) SA-β-gal staining of macrophages. (C–F) Immunofluorescence of TSPCs for (C) P16, (D) SOX2, (E) SCX, and (F) Tenomodulin (TNMD) with F-actin. (G) Quantification of P16, SOX2, SCX, and TNMD levels. (H) Proposed mechanism: LT-NPs-NIR promote an M1-to-M2 macrophage shift and regulate TSPC senescence/stemness balance to favor tenogenic repair, potentially via STING/NF-κB signaling. Scale bars: 100 μm (B); 50 μm (C–E); 100 μm (F). Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Journal: Bioactive Materials

Article Title: On-demand mild photothermal cascade platform reprogramming mitochondrial immunity for tendon rejuvenation

doi: 10.1016/j.bioactmat.2026.01.004

Figure Lengend Snippet: LT-NPs-NIR modulate macrophage polarization and enhance TSPC-mediated tenogenic repair in a Transwell co-culture system. (A) Schematic of the Transwell co-culture setup. (B) SA-β-gal staining of macrophages. (C–F) Immunofluorescence of TSPCs for (C) P16, (D) SOX2, (E) SCX, and (F) Tenomodulin (TNMD) with F-actin. (G) Quantification of P16, SOX2, SCX, and TNMD levels. (H) Proposed mechanism: LT-NPs-NIR promote an M1-to-M2 macrophage shift and regulate TSPC senescence/stemness balance to favor tenogenic repair, potentially via STING/NF-κB signaling. Scale bars: 100 μm (B); 50 μm (C–E); 100 μm (F). Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Article Snippet: After washing, cells were incubated with primary antibodies against Ki67 (ab15580, Abcam), Phosphorylated Histone H2AX (γ-H2AX) (ab81299, Abcam), SOX2 (sc-365964, Santa Cruz), Type I Collagen (COL1) (ab138492, Abcam), tenomodulin (TNMD) (ab203676, Abcam; sc-51813, Santa Cruz), Scleraxis (SCX) (sc-518082, Santa Cruz), IRF3 (ab68481, Abcam), Transcription Factor p65/RELA (P65) (A22331, Abclonal), Cyclin-Dependent Kinase Inhibitor 2A (p16INK4a) (P16) (sc-1661, Santa Cruz), P53 (10442-1-AP, Proteintech), Inducible Nitric Oxide Synthase (iNOS) (ab178945, Abcam), Arginase-1(Arg-1) (ab96183, Abcam), HSP70 (sc-32239, Santa Cruz), IL-6 (ab233706, Abcam), Matrix Metalloproteinase 13 (MMP13) (ab39012, Abcam), Double-stranded DNA (dsDNA) Marker (sc-58749, Santa Cruz), and Translocase of Outer Mitochondrial Membrane 20 (TOMM20) (11802-1-AP, Proteintech).

Techniques: Co-Culture Assay, Staining, Immunofluorescence

Molecular assessment of tendon repair and systemic biosafety. (A) Representative immunofluorescence images of inflammatory, matrix-degrading, tenogenic, and senescence markers, alongside macrophage phenotypes in repaired tendons. (B) Correlation analysis integrating molecular and functional recovery. Bar charts (left Y-axis) display the relative fluorescence intensity of the indicated markers, overlaid with line graphs (right Y-axis) showing the fold change in biomechanical properties (Ultimate Load and Tensile Modulus). Note the inverse correlation between SASP factors (IL-6, MMP13, P16) and mechanical strength. (C) Western blot analysis of the STING pathway, senescence indicators, and heterotopic ossification markers (OCN, SOX9, BMP-2). (D, E) Systemic biosafety evaluation via H&E staining of major organs (D) and blood biochemistry analysis (E) showing no toxicity. Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Journal: Bioactive Materials

Article Title: On-demand mild photothermal cascade platform reprogramming mitochondrial immunity for tendon rejuvenation

doi: 10.1016/j.bioactmat.2026.01.004

Figure Lengend Snippet: Molecular assessment of tendon repair and systemic biosafety. (A) Representative immunofluorescence images of inflammatory, matrix-degrading, tenogenic, and senescence markers, alongside macrophage phenotypes in repaired tendons. (B) Correlation analysis integrating molecular and functional recovery. Bar charts (left Y-axis) display the relative fluorescence intensity of the indicated markers, overlaid with line graphs (right Y-axis) showing the fold change in biomechanical properties (Ultimate Load and Tensile Modulus). Note the inverse correlation between SASP factors (IL-6, MMP13, P16) and mechanical strength. (C) Western blot analysis of the STING pathway, senescence indicators, and heterotopic ossification markers (OCN, SOX9, BMP-2). (D, E) Systemic biosafety evaluation via H&E staining of major organs (D) and blood biochemistry analysis (E) showing no toxicity. Significance: ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Article Snippet: After washing, cells were incubated with primary antibodies against Ki67 (ab15580, Abcam), Phosphorylated Histone H2AX (γ-H2AX) (ab81299, Abcam), SOX2 (sc-365964, Santa Cruz), Type I Collagen (COL1) (ab138492, Abcam), tenomodulin (TNMD) (ab203676, Abcam; sc-51813, Santa Cruz), Scleraxis (SCX) (sc-518082, Santa Cruz), IRF3 (ab68481, Abcam), Transcription Factor p65/RELA (P65) (A22331, Abclonal), Cyclin-Dependent Kinase Inhibitor 2A (p16INK4a) (P16) (sc-1661, Santa Cruz), P53 (10442-1-AP, Proteintech), Inducible Nitric Oxide Synthase (iNOS) (ab178945, Abcam), Arginase-1(Arg-1) (ab96183, Abcam), HSP70 (sc-32239, Santa Cruz), IL-6 (ab233706, Abcam), Matrix Metalloproteinase 13 (MMP13) (ab39012, Abcam), Double-stranded DNA (dsDNA) Marker (sc-58749, Santa Cruz), and Translocase of Outer Mitochondrial Membrane 20 (TOMM20) (11802-1-AP, Proteintech).

Techniques: Immunofluorescence, Functional Assay, Fluorescence, Western Blot, Staining

Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with CDK and NOTCH inhibitors starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.

Journal: Alzheimer's & Dementia

Article Title: Human iPSC‐derived GABAergic interneuron transplantation restores circuit balance and cognitive function in an Alzheimer's disease model

doi: 10.1002/alz.71378

Figure Lengend Snippet: Generation of hiPSC‐derived MGE‐pINs. (A) Schematic illustration of generation of iPSC‐derived MGE‐pINs. (B) Immunocytochemistry of iPSC‐derived MGE progenitor cells after 3 weeks of differentiation (from three independent iPSC lines). Scale bar = 50 µm. (C) Immunocytochemistry of 5‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor starting at 3 weeks of differentiation. Scale bar = 50 µm. (D) Immunocytochemistry of 7‐week‐old pINs derived from iPSCs after 2 weeks of treatment with MEK inhibitor combined with CDK and NOTCH inhibitors starting at 5 weeks of differentiation. Scale bar = 50 µm. (E) Quantitative analysis of 3‐week‐old MGE progenitor cells derived from iPSCs. (F) Quantitative analysis of 5‐week‐old pINs derived from iPSCs. (G) Quantitative analysis of 7‐week‐old pINs derived from iPSCs. Data were presented as mean ± SEM ( n = 3 hiPSC lines). ERBB4, Erb‐B2 receptor tyrosine kinase 4; FOXG1, Forkhead box G1; GABA, gamma‐aminobutyric acid; hiPSC, human induced pluripotent stem cell; KI67, Ki‐67 antigen; LHX6, LIM homeobox 6; LHX8, LIM homeobox 8; MAF, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog; MAFB, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B; MGE, medial ganglionic eminence; NKX2‐1, NK2 homeobox 1; OCT4, octamer‐binding transcription factor 4; SOX2, SRY‐box transcription factor 2; SOX6, SRY‐box transcription factor 6.

Article Snippet: From week 5 to week 7, in addition to the continued treatment with the MEK inhibitor, NOTCH inhibitors (DAPT 10 μM; HY‐13027, MCE) and cyclin‐dependent kinase (CDK) inhibitors (PD0332991 2 μM; MCE, HY‐50767) were introduced to induce cell cycle exit in the cells during this stage.

Techniques: Derivative Assay, Immunocytochemistry, Binding Assay